What's fueling the biotech engine—2011 to 2012

  title={What's fueling the biotech engine—2011 to 2012},
  author={Saurabh Aggarwal},
  journal={Nature Biotechnology},
Sales in the biologics sector show modest but healthy growth rates for the fourth consecutive year, with cancer drugs garnering the greatest revenues. As the diabetes epidemic grows and innovation of insulins continues, drug companies in that space are moving up in the ranks. 

What's fueling the biotech engine—2012 to 2013

Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be until

A survey of breakthrough therapy designations

As of last month, 41 products have been granted breakthrough therapy designations by the US Food and Drug Administration—drugs against cancer, hepatitis C and monogenetic diseases predominate.

Mammalian cell cultures for biologics manufacturing.

An overview of the biologics market is presented, including analysis of sales and approvals; as well as a review of industrial production cell lines and cell culture operations.

Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story

  • T. Mor
  • Biology
    Biotechnology Letters
  • 2015
The foresight to select this particular therapeutic product for development, flawless production pipeline, and serendipity seem to provide the key in explaining how ELELYSO became the first plant-derived biologic to achieve approval by Food and Drug Administration.

Natural product drug delivery: A special challenge?




What's fueling the biotech engine--2010 to 2011.

In the past year, biologics sector sales grew by single digits, driven by monoclonal antibodies and insulin products. New product launches are showing mixed results and are facing rising challenges

What's fueling the biotech engine—2009–2010

Last year, the biologics sector managed single-digit growth in the United States, driven mainly by products indicated for oncology, diabetes and autoimmune disorders. Lurking on the horizon, though,

Targeted cancer therapies

Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of the existence of high unmet need for improved treatments of multiple types of cancer and the substantial market success of targeted cancer therapies launched in the past decade.

The past 200 years in diabetes.

  • K. Polonsky
  • Medicine
    The New England journal of medicine
  • 2012
Progress in the understanding, diagnosis, and management of diabetes during the past 200 years is described.

Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis

  • K. Garber
  • Biology, Medicine
    Nature Biotechnology
  • 2011
467 JAK inhibitors like tofacitinib tread a fine line between therapeutic down-modulation of autoimmunity and outright immunosuppression. (Tofacitinib was first conceived as an immunosuppressant for

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

FDA analyzed the results of two single-arm trials, enrolling 102 patients with Hodgkin lymphoma and 58 patients with sALCL, finding that the most common adverse reactions were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory infection, diarrhea, pyrexia, rash and cough.

Bevacizumab in the treatment of ovarian cancer

  • E. HanB. Monk
  • Biology, Medicine
    Expert review of anticancer therapy
  • 2007
Bvacizumab offers a novel therapeutic modality in the treatment of epithelial ovarian cancers and has been generally well tolerated in ovarian cancer patients, but recent reports on increased risk of gastrointestinal perforations have gained attention.